FDA approves adult treatment for lymphoma

The FDA approved AstraZeneca's new treatment for adults with a rare, but fast-growing, type of non-Hodgkin lymphoma.

The drug, Calquence, is used to combat Mantle cell lymphoma after a prior treatment has failed. It is a kinase inhibibitor that blocks an enzyme the cancer needs to multiply and spread.

"Mantle cell lymphoma is a particularly aggressive cancer," said Richard Pazdur, MD, director of the FDA's Oncology Center of Excellence. "For patients who have not responded to treatment or have relapsed, Calquence provides a new treatment option that has shown high rates of response for some patients in initial studies."

The drug was approved using the FDA's accelerated approval pathway.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Whitepapers

Featured Webinars